Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis

Erin M. Vigil, Yasir Jamal Sepah, Anthony L. Watters, Mohammad A. Sadiq, Mehreen Ansari, Millena G. Bittencourt, Mohamed A. Ibrahim, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalArticle

Abstract

Background: The National Eye Institute 39-Question Visual Function Questionnaire (NEI VFQ-39) is an indicator of vision-related quality of life (QoL). The NEI VFQ-39 is used to assess the QoL in patients with non-infectious posterior uveitis, intermediate uveitis, or panuveitis, treated with subconjunctival (SCJ) or intravitreal (IVT) sirolimus as an immunomodulatory therapeutic (IMT) agent, delivered subconjunctivally (SCJ) or intravitreally (IVT) (the SAVE Study). Thirty subjects with non-infectious uveitis were randomized (SCJ:IVT, 1:1) for a prospective clinical trial. The 39-Question Visual Function Questionnaire (VFQ-39) was administered at baseline (BL), month 6 (M6), and month 12 (M12) visits. The survey measures self-reported vision health status for patients with chronic eye disease and assesses the effects of visual impairment on both task-oriented visual function and general health domains. In accordance to the NEI-VFQ Manual, each patient’s questionnaire was converted to a scaled score between 0 (worst) and 100 (best), and median scores were calculated for each of the subcategories and overall composite score at BL, M6, and M12. Wilcoxon signed-rank test was performed. Results: Twenty-six patients completed the VFQ-39 at BL and M6, whereas 23 patients completed it at M12. Patients showed a significant improvement in pooled composite scores from BL to M6 and BL to M12. Analysis by treatment groups showed that intravitreal injection of sirolimus is better tolerated. Conclusions: Sirolimus has demonstrated bioactivity as an IMT and corticosteroid-sparing agent to treat non-infectious uveitis. Patients receiving intravitreal injection of sirolimus showed overall improvement of vision-related health while those receiving subconjunctival injections did not. Larger randomized control trials with sirolimus are indicated to validate these results. Trial registration: ClinicalTrials.gov: NCT00908466

LanguageEnglish (US)
JournalJournal of Ophthalmic Inflammation and Infection
Volume5
Issue number1
DOIs
StatePublished - Dec 1 2015

Fingerprint

Intravitreal Injections
Uveitis
Sirolimus
Quality of Life
Safety
Therapeutics
Intermediate Uveitis
National Eye Institute (U.S.)
Panuveitis
Posterior Uveitis
Eye Diseases
Vision Disorders
Health
Nonparametric Statistics
Health Status
Adrenal Cortex Hormones
Chronic Disease
Clinical Trials
Injections
Surveys and Questionnaires

Keywords

  • Intravitreal
  • mTOR
  • Sirolimus
  • Uveitis

ASJC Scopus subject areas

  • Ophthalmology
  • Infectious Diseases

Cite this

Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis : a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis. / Vigil, Erin M.; Sepah, Yasir Jamal; Watters, Anthony L.; Sadiq, Mohammad A.; Ansari, Mehreen; Bittencourt, Millena G.; Ibrahim, Mohamed A.; Do, Diana V.; Nguyen, Quan Dong.

In: Journal of Ophthalmic Inflammation and Infection, Vol. 5, No. 1, 01.12.2015.

Research output: Contribution to journalArticle

@article{d5c16087c19f47e2aaafb51bacd10ba3,
title = "Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis",
abstract = "Background: The National Eye Institute 39-Question Visual Function Questionnaire (NEI VFQ-39) is an indicator of vision-related quality of life (QoL). The NEI VFQ-39 is used to assess the QoL in patients with non-infectious posterior uveitis, intermediate uveitis, or panuveitis, treated with subconjunctival (SCJ) or intravitreal (IVT) sirolimus as an immunomodulatory therapeutic (IMT) agent, delivered subconjunctivally (SCJ) or intravitreally (IVT) (the SAVE Study). Thirty subjects with non-infectious uveitis were randomized (SCJ:IVT, 1:1) for a prospective clinical trial. The 39-Question Visual Function Questionnaire (VFQ-39) was administered at baseline (BL), month 6 (M6), and month 12 (M12) visits. The survey measures self-reported vision health status for patients with chronic eye disease and assesses the effects of visual impairment on both task-oriented visual function and general health domains. In accordance to the NEI-VFQ Manual, each patient’s questionnaire was converted to a scaled score between 0 (worst) and 100 (best), and median scores were calculated for each of the subcategories and overall composite score at BL, M6, and M12. Wilcoxon signed-rank test was performed. Results: Twenty-six patients completed the VFQ-39 at BL and M6, whereas 23 patients completed it at M12. Patients showed a significant improvement in pooled composite scores from BL to M6 and BL to M12. Analysis by treatment groups showed that intravitreal injection of sirolimus is better tolerated. Conclusions: Sirolimus has demonstrated bioactivity as an IMT and corticosteroid-sparing agent to treat non-infectious uveitis. Patients receiving intravitreal injection of sirolimus showed overall improvement of vision-related health while those receiving subconjunctival injections did not. Larger randomized control trials with sirolimus are indicated to validate these results. Trial registration: ClinicalTrials.gov: NCT00908466",
keywords = "Intravitreal, mTOR, Sirolimus, Uveitis",
author = "Vigil, {Erin M.} and Sepah, {Yasir Jamal} and Watters, {Anthony L.} and Sadiq, {Mohammad A.} and Mehreen Ansari and Bittencourt, {Millena G.} and Ibrahim, {Mohamed A.} and Do, {Diana V.} and Nguyen, {Quan Dong}",
year = "2015",
month = "12",
day = "1",
doi = "10.1186/s12348-015-0044-1",
language = "English (US)",
volume = "5",
journal = "Journal of Ophthalmic Inflammation and Infection",
issn = "1869-5760",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis

T2 - Journal of Ophthalmic Inflammation and Infection

AU - Vigil,Erin M.

AU - Sepah,Yasir Jamal

AU - Watters,Anthony L.

AU - Sadiq,Mohammad A.

AU - Ansari,Mehreen

AU - Bittencourt,Millena G.

AU - Ibrahim,Mohamed A.

AU - Do,Diana V.

AU - Nguyen,Quan Dong

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: The National Eye Institute 39-Question Visual Function Questionnaire (NEI VFQ-39) is an indicator of vision-related quality of life (QoL). The NEI VFQ-39 is used to assess the QoL in patients with non-infectious posterior uveitis, intermediate uveitis, or panuveitis, treated with subconjunctival (SCJ) or intravitreal (IVT) sirolimus as an immunomodulatory therapeutic (IMT) agent, delivered subconjunctivally (SCJ) or intravitreally (IVT) (the SAVE Study). Thirty subjects with non-infectious uveitis were randomized (SCJ:IVT, 1:1) for a prospective clinical trial. The 39-Question Visual Function Questionnaire (VFQ-39) was administered at baseline (BL), month 6 (M6), and month 12 (M12) visits. The survey measures self-reported vision health status for patients with chronic eye disease and assesses the effects of visual impairment on both task-oriented visual function and general health domains. In accordance to the NEI-VFQ Manual, each patient’s questionnaire was converted to a scaled score between 0 (worst) and 100 (best), and median scores were calculated for each of the subcategories and overall composite score at BL, M6, and M12. Wilcoxon signed-rank test was performed. Results: Twenty-six patients completed the VFQ-39 at BL and M6, whereas 23 patients completed it at M12. Patients showed a significant improvement in pooled composite scores from BL to M6 and BL to M12. Analysis by treatment groups showed that intravitreal injection of sirolimus is better tolerated. Conclusions: Sirolimus has demonstrated bioactivity as an IMT and corticosteroid-sparing agent to treat non-infectious uveitis. Patients receiving intravitreal injection of sirolimus showed overall improvement of vision-related health while those receiving subconjunctival injections did not. Larger randomized control trials with sirolimus are indicated to validate these results. Trial registration: ClinicalTrials.gov: NCT00908466

AB - Background: The National Eye Institute 39-Question Visual Function Questionnaire (NEI VFQ-39) is an indicator of vision-related quality of life (QoL). The NEI VFQ-39 is used to assess the QoL in patients with non-infectious posterior uveitis, intermediate uveitis, or panuveitis, treated with subconjunctival (SCJ) or intravitreal (IVT) sirolimus as an immunomodulatory therapeutic (IMT) agent, delivered subconjunctivally (SCJ) or intravitreally (IVT) (the SAVE Study). Thirty subjects with non-infectious uveitis were randomized (SCJ:IVT, 1:1) for a prospective clinical trial. The 39-Question Visual Function Questionnaire (VFQ-39) was administered at baseline (BL), month 6 (M6), and month 12 (M12) visits. The survey measures self-reported vision health status for patients with chronic eye disease and assesses the effects of visual impairment on both task-oriented visual function and general health domains. In accordance to the NEI-VFQ Manual, each patient’s questionnaire was converted to a scaled score between 0 (worst) and 100 (best), and median scores were calculated for each of the subcategories and overall composite score at BL, M6, and M12. Wilcoxon signed-rank test was performed. Results: Twenty-six patients completed the VFQ-39 at BL and M6, whereas 23 patients completed it at M12. Patients showed a significant improvement in pooled composite scores from BL to M6 and BL to M12. Analysis by treatment groups showed that intravitreal injection of sirolimus is better tolerated. Conclusions: Sirolimus has demonstrated bioactivity as an IMT and corticosteroid-sparing agent to treat non-infectious uveitis. Patients receiving intravitreal injection of sirolimus showed overall improvement of vision-related health while those receiving subconjunctival injections did not. Larger randomized control trials with sirolimus are indicated to validate these results. Trial registration: ClinicalTrials.gov: NCT00908466

KW - Intravitreal

KW - mTOR

KW - Sirolimus

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=84928684518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928684518&partnerID=8YFLogxK

U2 - 10.1186/s12348-015-0044-1

DO - 10.1186/s12348-015-0044-1

M3 - Article

VL - 5

JO - Journal of Ophthalmic Inflammation and Infection

JF - Journal of Ophthalmic Inflammation and Infection

SN - 1869-5760

IS - 1

ER -